A CLINICAL STUDY OF HORMONE RECEPTOR STATUS IN CARCINOMA BREAST
Autor: | Josephine Pudhumai Selvi, Karthik Manohar, Sivanupandian Sivasubramanian |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
medicine.medical_specialty biology lcsh:R5-130.5 business.industry medicine.medical_treatment Oestrogen Receptor (ER) Progesterone Receptor (PR) Estrogen receptor HER2/Neu medicine.disease Contralateral Breast Carcinoma HER2/neu Breast cancer Internal medicine biology.protein Medicine Male Breast Carcinoma business Breast carcinoma lcsh:General works Tamoxifen Mastectomy medicine.drug |
Zdroj: | Journal of Evidence Based Medicine and Healthcare, Vol 4, Iss 52, Pp 3201-3205 (2017) |
ISSN: | 2349-2570 2349-2562 |
DOI: | 10.18410/jebmh/2017/635 |
Popis: | AIM OF THE STUDY: The aim of the study is to assess the incidence of hormone receptor positivity in females with carcinoma breast in relation to its clinical and pathological characteristics and thereby predicting the tumor response to endocrine therapy and to formulate the adjuvant treatment modality. MATERIALS AND METHODS: The study sample included 75 female patients with carcinoma breast. They were selected from the general surgical wards of Tirunelveli medical college hospital and thye study was done for a period of 18 months. Biopsy samples (either Trucut biopsy or postop mastectomy specimes) were sent to pathology lab where they were processed and analysed for the histological subtype of the tumor, its pathological grading and the clearance of resected margins of the tumor. Hormonal receptor assay was done using Immunohistochemistry technique in our college pathology department and results were interpreted. Inclusion criteria: 1. Clinically diagnosed breast malignancy in females of all age groups 2. Age of patient, tumor size, histological subtype and grading of the tumor 3. Trucut biopsy and mastectomy specimens Exclusion criteria: 1. Patients already treated for contralateral breast carcinoma 2. Male breast carcinoma RESULTS: In my study a total of 75 female patients with breast cancer in my institute were studied. the incidence of ER, PR, Her2 neu receptors among them correlating with age, tumor size, histological type and the pathological grading was evaluated. 52 patients (69.33%) were positive for estrogen receptor and 23 (30.66%) were negative. 39 patients (52%) were progesterone receptor positive and 36 (48%) were progesterone receptor negative. 28 (37.33%) patients had Her2 receptor positive and 47 (62.66%) were negative. Most of the tumors in women above45 years of age were hormone receptor positive. In women younger than 45 years both positive and negative were nearly equal. CONCLUSION: These results were comparable with the previous studies and thus reinforce the usefulness of estimation of the receptor status for treatment purpose in breast carcinoma. The patients with hormone receptor positivity in my study received endocrine therapy with tamoxifen. |
Databáze: | OpenAIRE |
Externí odkaz: |